A team of Japanese scientists identified two compounds in coffee that could inhibit prostate cancer growth. The study was conducted on lab mice models and focused on drug-resistant cancer cells. The research and its results are presented at the European Association of Urology congress in Barcelona, but the study was also released in the journal The Prostate.
This study is the first to show that coffee has beneficial effects against prostate cancer cells growth. As the researchers reported, specific types of coffee can protect against or slow down some forms of cancer. Now, the Japanese scientists focused on two compounds in coffee – kahweol acetate and cafestol.
Both those compounds inhibited the development of drug-resistant prostate cancer cells in animal models. However, no human tests have been conducted until this moment, but further studies are planned.
Recent Research Showed That Coffee Could Inhibit Prostate Cancer
“We found that kahweol acetate and cafestol inhibited the growth of the cancer cells in mice, but the combination seemed to work synergistically, leading to a significantly slower tumor growth than in untreated mice. After 11 days, the untreated tumors had grown by around 3 and a half times the original volume (342%), whereas the tumors in the mice treated with both compounds had grown by around just over one and a half (167%) times the original size,” explained the study’s leader, Dr. Hiroaki Iwamoto from the Department of Integrative Cancer Therapy and Urology at the Kanazawa University.
Both kahweol acetate and cafestol are present in Arabica coffee, and they are hydrocarbons. Also, coffee-making processes influence the presence of both those compounds in the final product. For example, filtered coffee doesn’t contain kahweol and cafestol at all, while in espresso, both substances are present.
“These are promising findings, but they should not make people change their coffee consumption. Coffee can have both positive and negative effects (for example it can increase hypertension), so we need to find out more about the mechanisms behind these findings before we can think about clinical applications. However, if we can confirm these results, we may have candidates to treat drug-resistant prostate cancer,” added Professor Atsushi Mizokami, the co-author of the study.